Five studies on the impact of diabetes drugs on CV outcomes get the editors' nod for the most promising results in 2017 diabetes research. Find out which 5!
Five studies that evaluated the impact on cardiovascular outcomes of traditional and newer diabetes drugs are the Patient Care editors' choice for the most promising results in 2017 diabetes research.Click through the slides above for at-a-glance summaries of:CVD REAL CANVAS REMOVAL DEVOTE ODYSSEY-DM-INSULINLEADER (CV, renal)
Sources: REAL Study: Kosiborod M, Cavender M, Norhammar A, et al.Lower rates of hospitalization for heart failure and all-cause death in new users of SGLT-2 inhibitors: The CVD-REAL study. Presented March 19, 2017 at the American College of Cardiology 66th Annual Scientific Session, Washington DC. Abstract 415-14. CANVAS: Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2017 Nov 13. pii: CIRCULATIONAHA.117.032038.
Source: Petrie JR, Chaturvedi N, Ford I, et al. for the REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:597-609. doi: 10.1016/S2213-8587(17)30194-8
Source: Marso SP, McGuire DK, Zinman B, et al for the DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377:723-732.
Source: Leiter LA, Cariou B, MÃ¼ller-Wieland D, Colhoun HM, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017;19:1781-1792.
Sources:CV outcomes: Marso SP, Daniels GH, Brown-Frandsen K, et al for the LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22. Renal outcomes: Mann JFE, Ãrsted DD, Brown-Frandsen K, Marso SP, et al for the LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839-848.